ACCEPTED MANUSCRIPT
[10]
[11]
[12]
A. Zumla, P. Nahid, S.T. Cole, Advances in the development of new tuberculosis drugs and
treatment regimens. Nat. Rev. Drug Discov. 12, (2013) 388-404.
K.N. Raymond, E.A. Dertz, S.S. Kim, Enterobactin: an archetype for microbial iron transport. Proc.
Natl. Acad. Sci. U. S. A. 100, (2003) 3584-3588.
J.J. De Voss, K. Rutter, B.G. Schroeder, H. Su, Y. Zhu, C.E. Barry III, The salicylate-derived
mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages.
Proc. Natl. Acad. Sci. U. S. A. 97, (2000) 1252-1257.
[13]
[14]
[15]
J. Zwahlen, S. Kolappan, R. Zhou, C. Kisker, P.J. Tonge, Structure and mechanism of MbtI, the
salicylate synthase from Mycobacterium tuberculosis. Biochemistry 46, (2007), 954-964.
A. Manos-Turvey, E.M. Bulloch, P.J. Rutledge, E.N. Baker, J.S. Lott, R.J. Payne, Inhibition studies of
Mycobacterium tuberculosis salicylate synthase (MbtI). ChemMedChem 5, (2010) 1067-1079.
A. Manos-Turvey, K.M. Cergol, N.K. Salam, E.M. Bulloch, G. Chi, A. Pang, W.J. Britton, N.P. West,
E.N. Baker, J.S. Lott, R.J. Payne, Synthesis and evaluation of M. tuberculosis salicylate synthase
(MbtI) inhibitors designed to probe plasticity in the active site. Org. Biomol. Chem. 10, (2012) 9223-
9236.
[16]
[17]
A.J. Harrison, M. Yu, T. Gårdenborg, M. Middleditch, R.J. Ramsay, E.N. Baker, J.S. Lott, The
structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the
siderophore mycobactin, reveals it to be a salicylate synthase. J. Bacteriol. 188, (2006) 6081-6091.
G. Chi, A. Manos-Turvey, P.D. O'Connor, J.M. Johnston, G.L. Evans, E.N. Baker, R.J. Payne, J.S.
Lott, E.M. Bulloch, Implications of binding mode and active site flexibility for inhibitor potency against
the salicylate synthase from Mycobacterium tuberculosis. Biochemistry 51, (2012) 4868-4879.
G. Wolber, T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and
their use as virtual screening filters. J. Chem. Inf. Model. 45, (2005) 160-169.
T. Tuccinardi, G. Poli, V. Romboli, A. Giordano, A. Martinelli, Extensive consensus docking
evaluation for ligand pose prediction and virtual screening studies. J. Chem. Inf. Model. 54, (2014)
2980-2986.
[18]
[19]
[20]
[21]
[22]
[23]
[24]
Poli, G.; Martinelli, A.; Tuccinardi, T. Reliability analysis and optimization of the consensus docking
approach for the development of virtual screening studies. J. Enzyme Inhib. Med. Chem. 31, (2016)
167-173.
G. Poli, N. Giuntini, A. Martinelli, T. Tuccinardi, Application of a FLAP-consensus docking mixed
strategy for the identification of new fatty acid amide hydrolase inhibitors. J. Chem. Inf. Model. 55,
(2015) 667-675.
C. Granchi, A. Capecchi, G. Del Frate, A. Martinelli, M. Macchia, F. Minutolo, T.Tuccinardi,
Development and validation of a docking-based virtual screening platform for the identification of
new lactate dehydrogenase inhibitors. Molecules 20, (2015) 8772-8790.
T. Tuccinardi, C. Granchi, F. Rizzolio, I. Caligiuri, V. Battistello, G. Toffoli, F. Minutolo, M. Macchia,
A. Martinelli, Identification and characterization of a new reversible MAGL inhibitor. Bioorg. Med.
Chem. 22, (2014) 3285-3291.
M. Vasan, J. Neres, J. Williams, D.J. Wilson, A.M.Teitelbaum, R.P. Remmel, C.C. Aldrich, Inhibitors
of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput
screening. ChemMedChem 5, (2010) 2079-2087.
[25]
[26]
C. Bissantz, B. Kuhn, M. Stahl, A medicinal chemist's guide to molecular interactions. J. Med. Chem.
53, (2010) 5061-5084.
R. Brosch, W.J. Philipp, E. Stavropoulos, M.J. Colston, S.T. Cole, S.V. Gordon, Genomic analysis
reveals variation between Mycobacterium tuberculosis H37Rv and the attenuated M. tuberculosis
H37Ra strain. Infect. Immun. 67, (1999) 5678–5774.
[27]
[28]
[29]
M. Sritharan, Iron homeostasis in Mycobacterium tuberculosis: mechanistic insight into siderophore-
mediated iron uptake. J. Bacteriol. 198, (2016) 2399-2409.
B. Schwyn, J.B. Neilands, Universal chemical assay for the detection and determination of
siderophores. Anal. Biochem. 160, (1987) 47–56.
F. Porta, A. Gelain, D. Barlocco, N. Ferri, S. Marchianò, V. Cappello, L. Basile, S. Guccione, F.
Meneghetti, S. Villa, A field‐based disparity analysis of new 1,2,5‐oxadiazole derivatives endowed
with antiproliferative activity. Chem. Biol. Drug Des. 90, (2017) 820-839.
[30]
[31]
[32]
Korb, O.; Monecke, P.; Hessler, G.; Stützle, T.; Exner, T. E. pharmACOphore: multiple flexible ligand
alignment based on ant colony optimization. J. Chem. Inf. Model. 2010, 50, 1669-1681.
O. Korb, T. Stützle, T.E. Exner, Empirical scoring functions for advanced protein-ligand docking with
PLANTS. J. Chem. Inf. Model. 49, (2009) 84-96.
D. A. Case, J.T. Berryman, R.M. Betz, D.S. Cerutti, T.E. Cheatham III, T.A. Darden, R.E. Duke, T.J.
Giese, H. Gohlke, A.W. Goetz, N. Homeyer, S. Izadi, P. Janowski, J. Kaus, A. Kovalenko, T.S. Lee,
S. LeGrand, P. Li, T. Luchko, R. Luo, B. Madej, K.M. Merz, G. Monard, P. Needham, H. Nguyen,
H.T. Nguyen, I. Omelyan, A. Onufriev, D.R. Roe, A. Roitberg, R. Salomon-Ferrer, C.L. Simmerling,
24